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Since the discovery of the endocannabinoid system consisting of cannabinoid receptors, endogenous ligands, and biosynthetic
and metabolizing enzymes, interest has been renewed in investigating the promise of cannabinoids as therapeutic agents.
Abundant evidence indicates that cannabinoids modulate immune responses. An inflammatory response is triggered when
innate immune cells receive a danger signal provided by pathogen- or damage-associated molecular patterns engaging patternrecognition receptors. Toll-like receptor family members are prominent pattern-recognition receptors expressed on innate
immune cells. Cannabinoids suppress Toll-like receptor-mediated inflammatory responses. However, the relationship between the
endocannabinoid system and innate immune system may not be one-sided. Innate immune cells express cannabinoid receptors and
produce endogenous cannabinoids. Hence, innate immune cells may play a role in regulating endocannabinoid homeostasis, and,
in turn, the endocannabinoid system modulates local inflammatory responses. Studies designed to probe the interaction between
the innate immune system and the endocannabinoid system may identify new potential molecular targets in developing therapeutic
strategies for chronic inflammatory diseases. This review discusses the endocannabinoid system and Toll-like receptor family and
evaluates the interaction between them.

1. Introduction
Cannabis sativa, better known as marijuana, has been used in
traditional medicine for millennia to treat various ailments
[1–4]. Development of cannabinoids from the cannabis plant
as therapeutic agents has been hindered by their recreational
abuse and addictive properties [5, 6]. Legalization of medical
marijuana is a growing trend during the past few years.
Medical marijuana is primarily used to treat glaucoma and to
stimulate appetite and prevent weight loss in AIDS and cancer
patients [1–4]. At present, the Food and Drug Administration has approved two cannabinoid medications, Marinol
containing a psychoactive phytocannabinoid and Cesamet
consisting of a synthetic cannabinoid, for the treatment
of nausea, emesis, and cachexia [6–8]. In several other
countries, Sativex has been approved to treat spasticity and
neuropathic pain in multiple sclerosis patients and pain in
patients with advanced cancer [1, 9]. It contains an equimolar
combination of psychoactive Δ9 -tetrahydrocannabinol and
nonpsychoactive cannabidiol, which are phytocannabinoids

[1, 9]. Nevertheless, the beneficial health effects of cannabinoids, for the most part, remain empirical and anecdotal.
However, discovery of two major cannabinoid receptors and
endogenous cannabinoids in humans provides the opportunity to understand the mechanisms of action and to develop
approaches for manipulating the cannabinoid system as
effective treatment for particular human diseases.
Familiar effects of marijuana result from phytocannabinoids acting as neurotransmitters or modulating neurotransmitter release that, in turn, causes euphoria, diminished pain, altered sensory perception, impaired memory,
and enhanced appetite [6, 7]. Neurological consequences
of cannabinoid exposure can be attributed to cannabinoid
receptors within the brain. Moreover, cannabinoids impact
other biological systems besides the central nervous system.
Numerous studies report that cannabinoids suppress in vitro
functions of human and animal immune cells, and animals
exposed to cannabinoids have decreased host resistance to
various pathogens and tumors (reviewed in [10–12]). Chronic
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cannabis use is associated with increased incidence of rhinitis, pharyngitis, asthma, bronchitis, and sexually transmitted
diseases [5, 9, 13, 14]. Besides social behavior contributing to
an increased rate of sexually transmitted diseases, depressed
immune functions could enhance susceptibility of marijuana
users to infections [5].
Because all immune cells examined so far express
cannabinoid receptors regardless of their cell lineage, all
types of immunity are sensitive to cannabinoid modulation
[10–12]. The importance of the cannabinoid system in regulating immune competency is revealed by altered immune
status in mice genetically deficient in cannabinoid receptors
[15]. In terms of adaptive immunity, cannabinoids usually
suppress primary antibody responses to T cell-dependent
antigens, induction of cytotoxic CD8+ T cells, and cytokine
production by helper CD4+ T cells, whereas other adaptive
immune responses are unaffected or enhanced [10–12]. The
current view is that cannabinoid exposure skews T cell
responses leading to suppression of cell-mediated immunity
and inflammatory reactions [10–12]. Furthermore, cannabinoids impact innate immunity that mediates inflammatory responses and promotes initiation of adaptive immune
responses. For example, alveolar macrophages isolated from
chronic marijuana users have compromised phagocytosis of
microorganisms, ability to kill bacteria, and production of
proinflammatory cytokines [16, 17]. These consequences of
drug use parallel in vitro cannabinoid suppression of immune
functions by monocytes, macrophages, and macrophage cell
lines of human and rodent origins [10–12]. My laboratory
reported that cannabinoids impair the ability of murine
macrophages to function as antigen-presenting cells resulting
in depressed helper CD4+ T cell responses [18–20]. Furthermore, macrophages from mice lacking cannabinoid receptor
expression are refractory to cannabinoid suppression of
antigen-presenting cell function [21, 22]. Therefore, cannabinoids can exert their influence on an immune response before
helper CD4+ T cell activation.
The endocannabinoid system consists not only of
cannabinoid receptors, but also of endogenous cannabinoids
and their biosynthetic and metabolizing enzymes. Macrophages are major producers of endogenous cannabinoids [23],
which may not be a coincidence. Both exogenous and
endogenous cannabinoids inhibit proinflammatory cytokine
production by macrophages stimulated through Toll-like
receptors (TLRs). TLRs play a crucial role in macrophages
sensing danger to trigger inflammatory responses. Conversely, activation of macrophages via TLRs alters their
expression of cannabinoid receptors and levels of endogenous
cannabinoids. This review discusses the endocannabinoid
system and TLR family and evaluates the interaction between
them with emphasis on the innate immune system.

2. Endocannabinoid System
2.1. Cannabinoid Receptors. Cannabinoid receptors encompass multiple subtypes (reviewed in [24–26]). Central
cannabinoid receptor type 1 (CB1) and peripheral cannabinoid receptor type 2 (CB2) are the predominant receptors
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and share approximately 44% homology [27–30]. Endogenous cannabinoids also bind Transient Receptor Potential
Vanilloid 1 receptor, a capsaicin receptor, which is structurally
different from CB1 and CB2 receptors [24–26]. The orphan
receptor GPR55 may be another receptor subtype, although
it has low homology to the other cannabinoid receptors [24–
26]. Other candidate receptors have been implicated by pharmacological and functional studies [24–26]. CB1 and CB2
receptors greatly differ in their tissue distribution. CB1 receptor, originally identified in rat cerebral cortex, is primarily
expressed in the central nervous system [27, 28]. This receptor
subtype is also expressed in various peripheral tissues, such as
testis, vascular endothelium, and small intestine [27, 28]. Its
expression is heterogeneous within the nervous system and is
mainly responsible for cannabinoid psychoactive properties.
In contrast, CB2 receptor was originally identified in the
promyelocytic leukemic cell line HL60 and is prevalent
within the immune system [29, 30]. All lineages of immune
cells express the CB2 receptor, although its expression level
varies among the cell types. In rank order, B cells express the
highest level followed by natural killer cells, macrophages,
monocytes, polymorphonuclear cells, and T cells [31]. CB2
receptor expression in healthy brains is limited to a few neurons in the brain stem [32, 33]. However, during neurological
diseases, such as multiple sclerosis and Alzheimer’s disease,
microglial cells, which are brain macrophages, express a high
level of CB2 receptor [33, 34]. Some immune cells, including
monocytes, also express the CB1 receptor [35–37]. When
both receptor subtypes are present in immune cells, the CB2
receptor is usually expressed at a significantly higher level
than the CB1 receptor [35–37]. Unlike CB1 receptor-mediated
cell activation, signal transduction through the CB2 receptor
lacks psychotropic effects [38, 39] making it an attractive
target for immunotherapy.
2.2. Exogenous and Endogenous Cannabinoids. Cannabis is
a complex mixture of over 100 cannabinoids along with
other classes of compounds that have pharmacological and
biological activities. Numerous synthetic analogues have
been produced based on structure-activity relationship studies [24, 25]. Many synthetic cannabinoid analogues have
biological effects similar to their natural counterparts [40, 41].
Cannabimimetic compounds are lipophilic molecules and
are classified into four main groups based on their chemical
structure [24, 25].
The classical group consists of dibenzopyran derivatives, and the phytocannabinoids fall into this group [24,
25]. Δ9 -Tetrahydrocannabinol is the major psychoactive
compound in marijuana and the best-studied cannabinoid. It is a partial agonist binding both CB1 and CB2
receptors and is an ingredient of Marinol and Sativex.
Another notable member is cannabidiol that is a nonpsychoactive ingredient of Sativex. Cannabidiol does not activate cannabinoid receptors and yet has biological activity,
including immune suppression. Instead, cannabidiol appears
to behave as a potent antagonist or inverse agonist [24,
25]. Cannabigerol is the common biosynthetic precursor
of Δ9 -tetrahydrocannabinol and cannabidiol [26]. Major
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homologues of Δ9 -tetrahydrocannabinol and cannabidiol are
Δ9 -tetrahydrocannabivarin and cannabidivarin, respectively,
with propyl side chains rather than pentyl side chains [26].
Other members are synthetic analogues of phytocannabinoids, and some synthetic compounds are selective receptor
agonists with higher affinity for one or other cannabinoid
receptor subtype.
Nonclassical cannabinoids are bicyclic and tricyclic analogues of Δ9 -tetrahydrocannabinol [24, 25]. These synthetic compounds lack a pyran ring. Several are selective
cannabinoid receptor agonists. The best-studied member
is (−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans4-(3-hydroxypropyl) cyclohexanol referred to as CP55,940,
which is a full nonselective agonist with higher potency than
Δ9 -tetrahydrocannabinol.
Cannabinoids belonging to the aminoalkylindole group
are very structurally different from classical and nonclassical compounds [24, 25]. They were initially developed as
potential analogues of nonsteroidal anti-inflammatory drugs
[42]. The most widely studied member is (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]1,4-benzoxazin-6-yl]-1-napthalenylmethanone called WIN
55,212-2 with slightly higher CB2 than CB1 receptor affinity.
Eicosanoids are the endogenous compounds and are
oxidized derivatives of 20-carbon fatty acids [24, 25].
Arachidonoyl-ethanolamide also called anandamide was the
first one isolated from porcine brain and was found to have
cannabimimetic activity [43]. Anandamide is an arachidonic
acid derivative that is highly sensitive to oxidation and
hydrolysis. It behaves as a partial agonist and has lower intrinsic activity for CB2 than for CB1 receptor. Another prominent
member is 2-arachionoyl glycerol, a monoglyceride, which
is more potent than anandamide. Initially, 2-arachionoyl
glycerol was isolated from intestine and brain [44, 45],
and its concentration in the brain is approximately 170-fold
higher than that of anandamide [46]. Because 2-arachionoyl
glycerol favors the CB2 receptor, it is viewed as the main
endocannabinoid to modulate immune functions. Several
synthetic analogues of anandamide have been produced to
achieve higher potency and efficacy.
Most cannabinoids exhibit stereoselectivity in pharmacological assays due to chiral centers in the molecules. Frequently, stereoselectivity is also observed in biological assays.
Classical and nonclassical cannabinoids and aminoalkylindoles are far more active than their corresponding enantiomer or stereoisomer [24, 25]. Stereoselectivity is one
criterion for receptor-mediated actions.
2.3. Cannabinoid Signal Transduction Pathways. Cannabinoid receptors are seven-transmembrane-spanning G
protein-coupled receptors [27–30]. The first evidence that
cannabinoid receptors are Gi/o protein-coupled receptors
was cannabinoid-induced inhibition of adenylate cyclase
leading to decreased intracellular cAMP level [47]. Pertussis
toxin inhibition of a cannabinoid effect confirms Gi/o
protein-mediated signal transduction [48]. G proteins are
heterotrimers, and upon activation the 𝛼 subunit dissociates
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from the 𝛽𝛾 dimer (Figure 1). The Gi/o 𝛼 subunit inhibits
adenylate cyclase decreasing intracellular cAMP levels
[40, 41]. In turn, cAMP-dependent protein kinase A activity
diminishes leading to less active transcription factor cAMP
response element-binding protein affecting gene expression
[40, 41]. The G protein 𝛽𝛾 dimer eventually leads to activation
of the mitogen-activated protein kinase (MAPK) pathways
and phosphatidylinositol-3 kinase (PI-3K) [49, 50].
MAPK and Akt regulation by cannabinoid receptor
signaling pathways is not well understood (Figure 1). PI3K inhibitors attenuate cannabinoid-induced activation of
MAPK in Chinese hamster ovary cells transfected with
human CB1 receptor cDNA [50]. This finding indicates that
PI-3K leads to Akt activation eventually causing p42/44 and
p38 MAPK activation. Similarly, Δ9 -tetrahydrocannabinol
activates the PI-3K/Akt pathway in epithelial cells leading to
Raf-1-mediated activation of p42/p44 MAPK [41]. In contrast, stimulation of rat microglial cells with 2-arachionoyl
glycerol causes MAPK activation that is dependent on protein
kinase C, not PI-3K [51]. Conversely, WIN 55,212-2 has
the opposite effect and inhibits p42/p44 MAPK activation
in murine splenic immune cells [52]. Akt may activate
mammalian target of rapamycin (mTOR) present in complex
1 (mTORC1), and, in turn, mTORC1 regulates protein synthesis, glucose metabolism, and autophagy. Rapamycin, a mTOR
inhibitor, blocks cannabinoid-induced neural progenitor cell
proliferation and cannabinoid-enhanced oligodendrocyte
differentiation [53, 54]. On the other hand, WIN 55,212-2
decreases mTORC1 activation in prostate cancer cells [55].
Furthermore, stimulation of promyelocytic HL60 cells with
2-arachionoyl glycerol or other cannabinoid agonists does
not activate Akt or mTOR [40]. Thus, cannabinoids may or
may not activate Akt, MAPKs, and mTOR depending on the
cannabinoid group type, cannabinoid concentration, and/or
cell type with differential cannabinoid receptor expression.
While CB1 and CB2 receptors share many signaling steps,
distinct differences have been identified in the signaling
pathways of theses receptors. CB1 receptor signaling can
cause increased intracellular Ca+2 level, which may result
from phospholipase C activation [40]. Stimulation through
the CB1 receptor also activates A-type and inwardly rectifying
potassium channels and inhibits N- and P/Q-type calcium
currents in neural cells [40, 41, 49]. Most notably, CB1
receptor signaling may increase intracellular cAMP levels
and cAMP-dependent protein kinase A activity due to the
receptor associating with Gs proteins [40]. Furthermore,
the CB1 receptor may associate with Gq proteins leading to
phospholipase D activation [40]. While the CB1 receptor may
couple to Gs or Gq proteins, the CB2 receptor does not [41].
2.4. Endocannabinoid Biosynthesis and Metabolism. Within
the central nervous system, anandamide and 2-arachionoyl
glycerol are not preformed molecules stored in vesicles but
rather are synthetized when cells are stimulated, such as
depolarization of neurons [56, 57]. Their synthesis depends
on increased intracellular Ca+2 concentration mainly due
to Ca+2 dependency of the biosynthetic enzymes [58–61].
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Figure 1: Cannabinoid receptor signal transduction pathway. Upon cannabinoid receptor engagement by a cannabinoid, the activated Gi/o 𝛼
subunit inhibits adenylate cyclase activity causing a decrease in cAMP, which, in turn, decreases PKA activity. The 𝛽𝛾 dimer activates PI3K,
which, in turn, activates PLC that ultimately leads to increased intracellular calcium levels. PI3K can active the MAPK pathways. Akt may
lead to mTORC1 activation. The 𝛽𝛾 dimer can, also, activate MKK leading to activation of the MAPK pathways. CB: cannabinoid; CB1R:
cannabinoid type 1 receptor; CB2R: cannabinoid type 2 receptor; AC: adenylate cyclase; PKA: protein kinase A; PI3K: phosphatidylinositol-3
kinase; PLC: phospholipase C; IP3 : inositol trisphosphate; mTORC1: mammalian target of rapamycin complex 1; MKK: mitogen-activated
protein kinase kinases; MAPK: mitogen-activated protein kinase; JNK: Jun kinases; Erk: extracellular signal-regulated kinases.

Anandamide is predominantly produced in a two-step enzymatic process starting with phosphatidylethanolamine that
is catalyzed by Ca+2 -dependent N-acyltransferase followed
by N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (reviewed in [62–65]). The critical precursors of
2-arachionoyl glycerol are sn-1-acyl-2-arachidonoylgylerols,
and multiple enzymatic pathways generate 2-arachionoyl precursors [63]. The main pathway involves phosphoinositideselective phospholipase C or similar phospholipases followed by two sn-1-selective diacylglycerol lipase isoenzymes
(reviewed in [62–65]). In contrast to anandamide, various stimuli in addition to Ca+2 -mobilization trigger 2arachionoyl glycerol synthesis in neural cells, epithelial
cells, and macrophages [56, 64]. Unlike anandamide, 2arachionoyl glycerol is an important precursor of other
molecules [63], which may explain their differential resting levels. In most cases, enhanced anandamide and 2arachionoyl glycerol biosynthesis is limited in time and
location, and, thus, their release affects only cells in the nearby
vicinity.
After release, endocannabinoids are rapidly internalized
into cells by an undefined mechanism, and a proposed
transporter has not been definitely identified. Intracellular anandamide is principally hydrolyzed by fatty acid
amide hydrolase, an integral plasma membrane protein

[66]. Similarly, internalized 2-arachionoyl glycerol is primarily hydrolyzed by monoacylglycerol lipase associated
with the plasma membrane [67]. Reaction products do not
activate cannabinoid receptors and may recycle back into
their respective biosynthetic pathways [63]. One hydrolysis product, arachidonic acid, may be metabolized by
various enzymes to produce prostaglandins, thromboxanes,
leukotrienes, and other biologically active compounds, which
are potent inflammatory mediators or immune suppressors.
Anandamide and 2-arachionoyl glycerol themselves may be
oxidized by cytochrome P450, cyclooxygenase-2, and 5- and
12-lipoxygenases [63, 65]. Some lipoxygenase products bind
both CB1 and CB2 receptors [25, 56, 57]. Hence, results from
metabolic enzyme inhibitors or enzyme deficient mice should
not presume to be caused by only increased endocannabinoid
levels.

3. Toll-Like Receptor Family
A fundamental characteristic of the immune system is the
ability to distinguish between self and non-self-molecules or
antigens. Immune cells are particularly adept at detecting
microbial antigens, and the subsequent immune response can
clear an infection and provide protection against a future
infection. Innate immunity represents the first line of defense
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against infectious diseases, and cells, such as neutrophils and
macrophages, are the first responders. Inflammation is the
initial immune response against infectious agents, and the
inflammatory response promotes initiation of an adaptive
immune response by antigen-specific T and B cells. However,
cells of innate immunity do not express antigen-specific
receptors, unlike T and B cells of adaptive immunity. Decades
ago, Janeway proposed a hypothesis that innate immune cells
utilize germline-encoded receptors that are antigen-selective
[68], and such receptors were eventually identified many
years later. Innate immune cells express pattern-recognition
receptors that bind conserved molecular patterns, and
engagement of these receptors transduces a signal allowing
cells to sense danger in the form of a pathogen or host cellular
damage [69, 70]. These receptors are present at the cell surface, in endocytic organelles, or in the cytoplasm permitting
perception of both extracellular and intracellular dangers.
The major receptor gene families based on protein domain
homology include TLRs, retinoid acid-inducible gene-1like receptors, absent in melanoma-2 receptors, C-type
lectin receptors, intracellular DNA sensors, and nucleotidebinding domain, leucine-rich repeat-containing receptors (or
nucleotide-binding, oligomerization domain-like receptors)
that are discussed in several comprehensive reviews [70–
76]. This review focuses on the TLR family, which has been
extensively investigated and was the first one discovered.
3.1. Toll-Like Receptor Family Members. Toll gene was first
identified in Drosophila as essential in regulating embryonic
development of dorsal-ventral polarity [77, 78]. In addition,
Toll has a critical role in resistance to fungal infections in
adult flies [79]. This latter discovery was key to understanding
innate inflammatory triggers and led to finding the mammalian homologues [80, 81]. Although the number of family
members varies among mammalian species, TLRs are evolutionarily conserved type I transmembrane proteins [70–76].
TLRs are predominantly expressed by innate immune cells,
especially dendritic cells and macrophages, while adaptive
immune B and T cells, and nonimmune cells, including
fibroblasts and epithelial cells, have limited TLR expression
[70–76]. Family members have a highly conserved cytoplasmic Toll/Interleukin-1 receptor (TIR) domain that initiates
signal transduction via recruitment of adaptor proteins [70–
76]. At present, 10 TLR chains have been identified in humans,
while TLR10 is a pseudogene in mice, but three additional
chains (TLR11 to TLR13) are expressed in mice [70–76]. Each
TLR recognizes a distinct set of molecular patterns [70–76].
Promiscuous ligand recognition, which is determined by the
leucine-rich repeat extracellular domain, is indispensable for
the handful of TLRs to mediate effective immune defenses
against an array of diverse pathogens.
3.2. Exogenous and Endogenous Ligands. Regarding mammalian host resistance, TLRs bind pathogen-associated
molecular patterns (PAMPs) present within microbial
molecules, but absent from mammalian molecules [70–75].
The broad gamut of ligand specificity ranges from hydrophobic lipids to hydrophilic nucleic acids. TLRs are divided into
two subfamilies based on their cellular location, and the
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following discussion will focus on the TLR chains expressed
in humans. TLR1 and TLR2, TLR4 through TLR6, and TLR10
are plasma membrane proteins, whereas TLR3 and TLR7
through TLR9 reside in membranes of endocytic organelles.
Interestingly, ligand recognition correlates with the cellular
location of TLRs [70–75]. Cell surface TLRs sense fungal
cell wall components (TLR2), bacterial lipopolysaccharides
(TLR4), lipoproteins (TLR1, TLR2, and TLR6), flagella
(TLR5), or peptidoglycans (TLR2). On the other hand,
intracellular TLRs are specific for viral double-stranded
RNA (TLR3), single-stranded RNA (TLR7 and TLR8), DNA
(TLR9), or unmethylated CpG DNA (TLR9). In contrast,
human TLR10 is an orphan receptor without a known ligand.
Receptor compartmentalization influences the types of
ligands accessible for cell activation. For example, endosomal
TLRs engage when virulent intracellular pathogens infect
cells, but do not signal when the pathogen remains outside
the cell. Although all TLRs possess a similar TIR domain,
cell surface and intracellular receptors, in general, utilize
different adaptor molecules to transduce a signal [70–75].
Cell surface TLR signaling mainly relies on TIR-containing
adaptor protein (TIRAP) and protein myeloid differentiation
primary response 88 (MyD88). Furthermore, TIR domaincontaining adaptor-inducing interferon-𝛽 (TRIF) and
TRIF-related adaptor molecule (TRAM), also, transmit TLR
signals. The different pairs of adaptor molecules activate
distinct transcription factors, and, hence, influence the
nature and outcome of the inflammatory response.
For many years, one puzzling aspect of innate immunity
has been inflammatory responses in the absence of an infection that contribute to tissue damage during autoimmune
diseases and chronic inflammatory diseases. Matzinger proposed that the immune system does not distinguish between
self and non-self-antigens per se but rather is designed to
detect danger [82]. The apparent paradox of sterile inflammation is resolved by realization that pattern-recognition
receptors, including TLRs, recognize endogenous ligands.
The endogenous molecules called damage-associated molecular patterns (DAMPs) are created or released upon tissue
injury or cell death [69, 76]. Heat shock protein 60 was the
first candidate DAMP reported to induce TLR4 activation
[83]. Within months, necrotic cells were shown to induce
proinflammatory gene expression and dendritic cell maturation via TLR2 [84, 85]. Since then, several DAMPs have been
identified, and some are intracellular molecules to which
innate immune cells are not normally exposed. Analogous
to PAMPs, cell surface and intracellular TLRs recognize
different types of DAMPs, although endogenous ligands have
not been identified for all TLRs [69, 76]. For example, TLR2
and TLR4 ligands include heat shock proteins, serum amyloid
A, and oxidized low-density lipoprotein. Intracellular TLR3
recognizes mRNA, and TLR9 binds antibody-chromatin
complexes. Recent evidence indicates that danger signals
provided by PAMPs and DAMPs synergistically activate
inflammatory responses.
3.3. MyD88-Dependent Signal Transduction Pathway. Functional TLRs form dimers and particular receptors associate with a coreceptor and/or an accessory molecule
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Figure 2: TLR signal transduction pathways. (a) Signaling through TLR4 by bacterial LPS. TLR4 forms a complex with LBP, MD2, and
CD14. When LPS binds TLR4, two adaptor complexes are recruited. The MyD88-dependent pathway activates IRAKs eventually leading to
activation of TAK1 that leads to activation of transcription factor NF-𝜅B and stimulates the MAPK pathways for transcription factor AP-1
activity. The TRIF-dependent pathway occurs within endosomes and activates RIP1, also resulting in TAK1 activation. Through TRAF3, IKKi
and TBK1 are activated leading to the activation of transfer transcription factor IRF-3. (b) Signal through TLR3 by nucleic acids occurs within
endosomes. When the receptor is occupied, TLR3 alone binds TRIF without TRAM. RIP1 is activated leading to the same subsequent events
as those during TLR4 signaling. TRIF also activates IKKi and TBK1 leading to transcription factor IRF-3 activation, but involves TRAF6,
not TRAF3. TLR: Toll-like receptor; LPS: lipopolysaccharide; LBP: LPS-binding protein; MD2: myeloid differentiation-2 protein; MyD88:
myeloid differentiation primary response 88; TIR: Toll/interleukin-1 receptor; TIRAP: TIR-containing adaptor protein; TRIF: TIR domaincontaining adaptor-inducing interferon-𝛽; TRAM: TRIF-related adaptor molecule; IL: interleukin; IRAK: IL-1R-associated kinases; TNF:
tumor necrosis factor; TRAF: TNF receptor-associated factors; TBK1: TANK-binding kinase-1; MAPK: mitogen-activated protein kinase;
RIP1: receptor-interacting serine/threonine-protein kinase 1; TAK1: tumor growth factor-𝛽-activated kinase 1; IKKi: inducible I𝜅B kinase-I;
IRF-3: interferon regulatory factor-3; AP-1: activator protein-1; NF-𝜅B: nuclear factor-𝜅B.

[69–76, 86]. Most TLRs form homodimers with TLR2 as
the notable exception pairing with TLR1 or TLR6. These
TLR2 heterodimers have different ligand specificities. When a
ligand binds, the TIR domains oligomerize recruiting adaptor
proteins that initiate downstream signaling events.
TLR4, the prototype and best-studied receptor, is unique
among TLRs using four adaptor molecules. The classic
TLR4 ligand is lipopolysaccharide (LPS) from Gram-negative
bacteria, which causes septic shock. The LPS response
requires a molecular complex (Figure 2(a)) consisting of
TLR4 homodimer, LPS-binding protein, CD14, and myeloid
differentiation-2 protein (MD-2) [69–76]. MD-2 is required
for TLR4 dimerization. Upon LPS exposure, the TLR4:MD2 complex concentrates within cholesterol-rich lipid rafts

containing CD14, which is anchored to the plasma membrane
by glycosylphosphatidylinositol. The LPS-binding protein, a
soluble serum protein that binds lipid A moiety, initiates
sequential transfer of LPS monomers to coreceptor CD14
and then to MD-2. Gioannini and Weiss estimate that
LPS monomers extracted from one bacterium are sufficient
to activate 1,000 macrophages [87]. Hence, sequential LPS
transfer is thought to heighten sensitivity of innate immune
cells, in particular macrophages.
Adaptor TIRAP binds the TIR domain of TLR4 but lacks
a signaling domain [70–75, 86]. TIRAP itself contains a TIR
domain that subsequently recruits adaptor MyD88 to the
TLR4 complex (Figure 2(a)). The MyD88-dependent signaling pathway triggers IL-1R-associated kinases and MAPKs
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culminating in activation of transcription factors, nuclear
factor- (NF-) 𝜅B, and activator protein-1. These transcription
factors induce nitric oxide and proinflammatory cytokine
production.
All TLRs except TLR3 utilize MyD88, and the other cell
surface receptors, also, interact with TIRAP similar to TLR4
and lead to NF-𝜅B activation [69–76, 86]. Similar to TLR4,
TLR2 heterodimers localize to lipid rafts and require MyD88
via TIRAP for signal transduction. However, TLR2/TLR1
activation involves coreceptor CD14, whereas CD36 serves
as the coreceptor for TLR2/6 [70, 88]. CD36 functions as
a scavenger receptor in monocytes and macrophages and
participates in phagocytosis and endocytosis [89]. CD36
might mediate TLR2/6 internalization to downregulate cell
activation.
3.4. TRIF-Dependent Signal Transduction Pathway. Unlike
other TLRs, TLR4 signals involve a second pair of adaptor
proteins resulting in type I interferon production (Figure 2(a)) and a second wave of NF-𝜅B activation [69–76,
86]. In this pathway, adaptor TRAM and TRIF molecules
drive cell activation. Analogous to TIRAP, TRAM lacks a
signaling domain and recruits a second adaptor molecule, in
this case TRIF, to the plasma membrane. TRIF recruits signaling molecules that, in turn, recruit inducible I𝜅B kinasei and TANK-binding kinase-1 to the complex. Ultimately,
transcription factor interferon regulatory factor- (IRF-) 3
becomes activated leading to type I interferon synthesis,
especially interferon-𝛽. Receptor-interacting protein kinase-1
activity eventually leads to TRIF-dependent MAPKs and NF𝜅B activation.
Both TIRAP and TRAM localize to the plasma membrane; however their binding to TLR4 appears to be mutually
exclusive [90]. Colocalization, time kinetics, and endocytosis
inhibition studies indicate that TRAM engages after TLR4
internalization [70, 72–75, 86]. A novel model of TLR4
signaling proposes that CD14 mediates trafficking of TLR4 to
the endosomes, whereupon the TRIF-dependent pathway is
induced [70, 72–75, 86]. Hence, the MyD88-dependent and
TRIF-dependent signaling pathways are sequestered from
each other, and commence at distinct cellular locations.
3.5. Intracellular TLR Signal Transduction Pathways. Intracellular TLRs stimulate cells by divergent pathways compared
with TLR4 [70, 72–75, 86]. Intracellular TLR7 to TLR9 do
not utilize the TRAM/TRIF pathway. Instead, engagement
of these receptors induces type I interferon production via
IRF7 and NF-𝜅B activation in a MyD88-dependent manner.
The alternative MyD88 pathway triggers IL-1R-associated
kinases to activate transcription factors IRF7 and NF-𝜅B.
On the other hand, TLR3 employs the adaptor TRIF protein
(Figure 2(b)) but does not need either TRAM or MyD88.
The high affinity TIR domain of TLR3 directly binds TRIF
in the absence of TRAM. Notably, a point mutation within
the TIR domain of TLR3 switches its specificity from TRIF to
MyD88 [91]. Similar to TLR4, this TRIF-dependent pathway
activates transcription factor IRF3 via TANK-binding kinase1 inducing robust interferon-𝛽 secretion.
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Cell activation by TLR signals is tightly regulated on
multiple levels. Critical regulatory mechanisms range from
TLR trafficking and cleavage to protein modification of
signaling molecules. Furthermore, negative regulators are
important in preventing autoimmune and inflammatory diseases. TLR recognition of PAMPs is crucial for host resistance
to infectious diseases, and individuals with defective TLR
responses are immune compromised. On the flip side, abnormal TLR activation by PAMPs, mutations in TLR signaling
molecules, and TLR activation by DAMPs are associated with
the development and pathogenesis of numerous diseases,
including autoimmune diseases, hypersensitivities, chronic
inflammatory diseases, cancer, and cardiovascular diseases.
Hence, cannabinoid modulation of TLR signal transduction
pathways may have beneficial or detrimental consequences
on human health.

4. Interaction between Cannabinoid and
Toll-Like Receptor Activation
Important innate immune cells expressing TLRs are monocytes, macrophages, microglial cells, and dendritic cells.
These myeloid cells are closely related. Monocytes circulate
in the blood and mature into macrophages or dendritic
cells depending on the stimulus. Microglial cells are resident macrophages in the brain. All these cells express
cannabinoid receptors, and cannabinoids influence their
immune functions. Of note, alveolar macrophages isolated
from chronic marijuana users are compromised in secreting
proinflammatory cytokines, such as tumor necrosis factor-𝛼
and interleukin-6, in response to LPS [16, 17]. This review
discusses cannabinoid modulation of TLR ligand responses
by innate immune cells, and vice versa.
4.1. Impact of Cannabinoids on Toll-Like Receptor Responses.
Cannabinoid studies regarding TLRs have concentrated
on bacterial LPS responses via TLR4 as a classic model
for inflammation (Table 1). For the most part, exogenous and endogenous cannabinoids interfere with proinflammatory cytokine and nitric oxide production by LPSor LPS/interferon-𝛾-stimulated monocytes, macrophages,
microglia, and macrophage cell lines in culture [10–12, 92,
93]. However, one study reported increased interleukin-1𝛽
secretion by LPS-activated resident peritoneal cells caused
by Δ9 -tetrahydrocannabinol [94] in opposition to other
investigations [95, 96]. Cannabinoids display biphasic doseresponse curves for cytokine secretion in some culture systems [96, 97], which may account for this apparent discrepancy. Interestingly, Δ9 -tetrahydrocannabinol decreases LPSinduced cyclooxygenase-2 expression in mouse macrophage
J774 cell line [93], which would diminish endocannabinoid
2-arachidonoyl-glycerol metabolism, thereby augmenting
immune suppression. In addition, chronic marijuana use
increases CB1 and CB2 receptor expression on peripheral
blood monocytes [98], which may enhance cannabinoid
sensitivity. Thus, exogenous cannabinoids may alter the
endocannabinoid system leading to greater suppression of the
LPS response.
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Table 1: Cannabinoid effects on in vitro TLR responses.

Cells

Stimulus

Alveolar macrophages

LPS

Monocytes

LPS

LPS
Thioglycollate-elicited macrophages
LPS/interferon-𝛾

Blood mononuclear cells

LPS

LPS
Microglial cells
LPS/interferon-𝛾
Dendritic cells
BV-2 cells

J774 cells

↓ inflammatory cytokines
↓ inflammatory cytokines
Impairs differentiation to
dendritic cells
↓ tumor necrosis factor-𝛼 protein
processing
↑ interleukin-1𝛽
↓ nitric oxide synthase-2
↓ nitric oxide
↑ interleukin-10
↓ interleukin-1𝛼
Biphasic dose-response
↓ cytokine mRNA
↑ IL-1 receptor antagonist
↓ nitric oxide
↑ interleukin-10
↓ nitric oxide

LPS

↓ TLR4 expression

LPS

↓ NF-𝜅B activity
↓ cytokine mRNA
↓ interferon-𝛽 mRNA

LPS

RAW 264.7 cells

LPS

TLR4-transfected HEK293 cells

LPS

Glioma U87MG cells

Effect

Peptidoglycan

↓ nitric oxide
↓ interleukin-6
↓ cyclooxygenase-2
↓ tumor necrosis factor-𝛼 protein
processing
↓ nitric oxide synthase-2
↓ nitric oxide
↓ NF-𝜅B activity
↓ interferon-𝛽 mRNA
↓ IRF3 activity

Baldwin et al. [16]
Pacifici et al. [17]
Zurier et al. [95]
Roth et al. [122]
Zheng and Specter [99]
Zhu et al. [94]
Coffey et al. [102]
Mestre et al. [92]
Correa et al. [109]
Watzl et al. [96]
Berdyshev et al. [97]
Puffenbarger et al. [103]
Molina-Holgado et al. [111]
Merighi et al. [123]
Correa et al. [110]
Waksman et al. [124]
Xu et al. [106]
More et al. [101]
Kozela et al. [125]
Chang et al. [93]

Fischer-Stenger et al. [100]
Jeon et al. [104]

Downer et al. [126]

↓ NF-𝜅B activity

Echigo et al. [105]
Downer et al. [127]
Downer et al. [126]

Downer et al. [126]

TLR3-transfected HEK293 cells

Polyinosinic:polycytidylic acid

↑ interferon-𝛽 mRNA
↑ IRF3 activity
↓ tumor necrosis factor-𝛼
↓ NF-𝜅B activity

Blood mononuclear cells

Polyinosinic:polycytidylic acid

↑ interferon-𝛽 mRNA
↓ tumor necrosis factor-𝛼

Cannabinoids directly impair TLR-induced cell activation in culture (Table 1). Δ9 -Tetrahydrocannabinol perturbs
posttranslational processing of tumor necrosis factor-𝛼 protein in LPS-activated mouse macrophages [99, 100]. Furthermore, cannabinoids diminish proinflammatory cytokine
production in LPS-stimulated mouse microglial BV-2 cell line
that is accompanied by decreased transcription factor NF𝜅B activity and corresponding cytokine mRNA levels [101].

Reference

LPS stimulates nitric oxide production and release through
induction of nitric oxide synthase-2 expression under NF𝜅B regulation. Similar to cytokine suppression, cannabinoids
attenuate nitric oxide release, nitric oxide synthase-2 gene
expression and enzymatic activity, and transcription factor NF-𝜅B activation in LPS- or LPS/interferon-𝛾-activated
myeloid cells [92, 102–104]. Analogously, cannabinoids suppress peptidoglycan-stimulated cell growth of a glioma cell
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Table 2: Cannabinoid effects on in vivo TLR responses.

Animal model

Cell or tissue
Blood & brain

LPS

Cardiovascular system
Blood

LPS-induced pulmonary
inflammation

C. parvum/LPS

D-Galactosamine/LPS

↓ inflammatory cytokines
CB1R & CB2R-mediated
↓ hypotensive response
↓ tumor necrosis factor-𝛼
↑ survival

Reference
Roche et al. [112]
Gallily et al. [115]

↓ tumor necrosis factor-𝛼
↓ neutrophil infiltration
CB2R-mediated

Berdyshev et al. [113]

↓ inflammatory cytokines
↑ survival
CB1R-mediated

Smith et al. [114]

Blood

Tomar et al. [116]

Liver

↓ inflammatory cytokine
↑ interleukin-10
↓ acute liver failure
↓ cell infiltration
CB2R-mediated
↑ survival
↑ interleukin-6
↑ tissue damage
↓ survival
↑ incidence & severity of induced
inflammatory various diseases

Tschöp et al. [118]

Bronchoalveolar fluid
Lungs

Blood
Sepsis in CB2R−/− mice

Effect

Lungs

CB2R−/− mice

CB1R/CB2R−/− mice
Alveolar macrophages
Dendritic cells

line via TLR2 with concomitant decreased NF-𝜅B activation
[105]. These results indicate that cannabinoids directly interfere with TLR signal transduction.
On the other hand, cannabinoids may also indirectly
suppress in vitro cytokine production (Table 1). For example,
a CB2 receptor-selective agonist prevents LPS-upregulated
TLR4 expression on mouse bone marrow dendritic cells
rendering the cells less LPS responsive [106], although a
similar cannabinoid effect upon TLR4 expression has not
been reported for other innate immune cells. Moreover,
cannabinoids induce apoptosis that has been proposed as
an immunosuppressive mechanism [107, 108]. However, the
majority of findings regarding cannabinoid inhibition of
TLR-mediated responses cannot be attributed to apoptosis or
cell toxicity. Lastly, cannabinoids may induce other immune
suppressive processes. Anandamide and a CB2 receptorselective agonist induce production of interleukin-10, an
inhibitory cytokine, in LPS/interferon-𝛾-activated myeloid
cells [109, 110]. CP55,940 induces interleukin-1 receptor
antagonist expression in LPS-stimulated microglial cells [111],
which interferes with interleukin-1 signals. Thus, multiple

↑ contact dermatitis
↑ delayed-type hypersensitivity
↑ Influenza-induced
inflammation
More mature phenotype
More mature phenotype

Gallily et al. [115]

Reviewed in Buckley [15]
& Malfitano et al. [117]
Karsak et al. [119]
Buchweitz et al. [120]
Karmaus et al. [121]

modes of action may mediate cannabinoid suppression of in
vitro LPS responses.
LPS administration in animals is frequently used as in
vivo models of inflammation and bacterial sepsis (Table 2).
A synthetic cannabinoid diminishes LPS-stimulated proinflammatory cytokine levels in the brain and blood of rats
[112]. In the LPS-induced pulmonary inflammation model,
exogenous and endogenous cannabinoids dose-dependently
decrease tumor necrosis factor-𝛼 level in bronchoalveolar
fluid and reduce neutrophil infiltration into the lungs in mice
[113]. Synthetic cannabinoids rescue C. parvum-primed mice
from LPS lethality and diminish serum proinflammatory
cytokine levels [114]. Likewise, a nonpsychoactive synthetic
cannabinoid abolishes LPS-induced hypotensive response in
rats and rescues mice from the lethal effects of LPS and
D-galactosamine coadministration [115]. A CB2 receptorselective agonist also protects against mortality and acute
liver failure, decreases proinflammatory cytokines levels,
and increases inhibitory interleukin-10 level in mice given
LPS and D-galactosamine [116]. Upon in vitro LPS stimulation, cytokine and nitric oxide production by macrophages
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from mice previously given Δ9 -tetrahydrocannabinol remain
suppressed without additional drug in the cultures [102].
Perhaps, cannabinoid immune suppression induced in vivo
may persist after drug removal. Therefore, the effects of
cannabinoids on LPS activation in several animal models, in
general, parallel the in vitro findings.
Involvement of cannabinoid receptors in suppressing
TLR responses has been established by multiple approaches.
One set of criteria is cannabinoid receptor-selective agonists causing inhibition and cannabinoid receptor-selective
antagonists reversing inhibition. Cannabinoid suppression of
proinflammatory cytokine and nitric oxide production is CB2
receptor-mediated in LPS-stimulated cultured cells, LPSinduced pulmonary inflammation, and LPS/galactosamineinduced acute liver failure [113, 116] (Table 2). On the other
hand, protection of C. parvum-primed mice from LPS lethality and diminished NF-kB activity in TLR2 ligand-stimulated
glioma cells are mediated through the CB1 receptor [105, 114],
whereas both cannabinoid receptors participate in decreasing
cytokine levels after in vivo LPS administration [112]. Mice
genetically deficient in cannabinoid receptor expression are
the best evidence for receptor participation. CB2 receptordeficient mice are highly susceptible to induced inflammatory diseases, including contact dermatitis, experimental
autoimmune encephalomyelitis, atherosclerosis, and carbon
tetrachloride-induced liver damage [15, 117]. Incidence and
severity of the diseases are exacerbated in the CB2 receptordeficient mice compared to wild-type mice [15, 117]. Importantly, the CB2 receptor-deficient mice have lower survival, more pronounced tissue damage, and increased serum
interleukin-6 levels in a sepsis model [118]. Mice lacking
both cannabinoid receptors have markedly heightened allergic inflammation leading to exacerbated contact dermatitis,
delayed-type hypersensitivity, and inflammatory responses
to Influenza virus [119–121]. Alveolar macrophages and bone
marrow dendritic cells from mice deficient in both cannabinoid receptors have a more mature phenotype, have increased
expression of major histocompatibility complex class I and
class II molecules, and are more efficient in activating T cells
[120, 121], suggesting that the absence of endocannabinoid
signals may alter differentiation and maturation of innate
immune cells towards hyperresponsiveness. Perhaps, the role
of the CB1 receptor is more readily detected in in vivo models
due to interactions among various cell types. The absence
of both cannabinoid receptors has a more dramatic impact
on the immune system, indicating the possible interplay
of cannabinoid receptors during disease processes, which
has important implications in developing cannabinoids as
therapeutic agents for inflammatory diseases.
Microglial cells play an important role in neuroinflammation and appear to be a special case in terms of cannabinoid
receptor-mediated immune suppression. General consensus
is that resting microglial cells express a low level of the
CB1 receptor and lack CB2 receptor expression [12, 56, 57].
However, microglial cells from diseased tissues or microglial
cells activated in culture gain CB2 receptor expression [12,
56, 57]. Criteria used for cannabinoid receptor involvement
in diminished proinflammatory cytokine secretion and nitric
oxide release from LPS-activated microglial cells in culture
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reveal all possible outcomes encompassing both cannabinoid
receptors, or the CB1, CB2, or no cannabinoid receptor
[103, 109, 111, 123–125]. A receptor-independent mechanism
despite cannabinoid receptor expression on the cells implies
that cannabinoid receptor expression is too low to exert a
biological effect, or the receptors are inactive. A receptorindependent mechanism may involve disruption of lipid rafts
due to the hydrophobicity of cannabinoids [141]. As discussed
above, lipid rafts are critical for proper assembly of the TLR4
and TLR2 complexes, and their disruption would contribute
to a decreased TLR response. Differences in agonist or
antagonist concentrations, and cell activation state among
the studies, may contribute to disparate findings concerning
cannabinoid receptor participation. Additional investigation
is needed to resolve this issue.
Cannabinoids exert immune suppression when innate
immune cells are activated, but not when the cells are
resting or quiescent. When direct suppression is cannabinoid
receptor-mediated, the two signal transduction pathways
(Figures 1 and 2(a)) would cross-talk. Transcription factor
NF-𝜅B is activated through the MyD88-dependent signal
transduction pathway via both TLR4 and TLR2. Hence,
cannabinoids must interfere with the MyD88-dependent
signal transduction pathway to decrease NF-𝜅B activity
along with diminishing cytokine production and cell growth
through TLR4 and TLR2. In some cases, cell permeable
cAMP to counteract the active Gi/o subunit reverses cannabinoid inhibition of cytokine secretion and nitric oxide release
[10–12, 102, 124] suggesting the involvement of decreased
protein kinase A activity in mediating suppression. However,
protein kinase A activity is not necessary for cytokine gene
expression in TLR-activated cells (Figure 2). Other studies
suggest cannabinoid regulation of p42/p44 MAPK activation
participates in immune suppression [41, 52]. Activation of the
MAPK pathways is required for cytokine gene transcription.
In this scenario, too much of a positive signal becomes
negative. Excessive MAPK activation may generate a negative
feedback loop. Although a remaining question is what is the
link between the cannabinoid and TLRs signaling pathways,
MAPKs are attractive candidates.
Cannabinoids augment interferon-𝛽 production during
the TLR3 ligand response (Table 1). Very few studies have
examined the impact of cannabinoids on TLR3 signal transduction and interferon-𝛽 production (Figure 2(b)), and,
thus, studies with nonimmune cells are discussed below.
Interferon-𝛽 is a type I interferon with antiviral and antiinflammatory activities and is a treatment for multiple
sclerosis patients [142]. WIN 55,212-2 does not suppress
but rather enhances interferon-𝛽 mRNA expression in
polyinosinic:polycytidylic acid-activated HEK293 cell line
transfected with TLR3 cDNA [127]. Interferon-𝛽 transcript
upregulation is accompanied by increased MAPK and transcription factor IRF3 activities; however tumor necrosis
factor-𝛼 secretion and transcription factor NF-𝜅B activity
decrease in the TLR3-transfected cells [127]. Analogously,
WIN 55,212-2 augments interferon-𝛽 mRNA expression
but decreases tumor necrosis factor-𝛼 secretion in polyinosinic:polycytidylic acid-activated primary astrocytes and
peripheral blood mononuclear cells from multiple sclerosis
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Table 3: Inflammatory effects on endocannabinoid system.

Cell or tissue

Stimulus in vitro or animal model

Macrophages

Thioglycollate in vivo

Effect

Reference

↑ CB2 receptor

Carlisle et al. [128]

Induces CB2 receptor

Walter et al. [129]
Maresz et al. [130]

LPS

↓ CB2 receptor

Carlisle et al. [128]
Cabral et al. [131]

Microglial cells

LPS in vivo

↑ CB2 receptor

Mukhopadhyay et al. [132]
Concannon et al. [133]

Blood mononuclear cells

LPS in vivo

Spleen & liver

LPS in vivo

Microglial cells
Thioglycollate-elicited
macrophages

Interferon-𝛾

↓ fatty acid amide hydrolase
activity
↓ 2-arachidonyl glycerol
hydrolytic activity

Wolfson et al. [134]
Szafran et al. [135]

LPS

↑ anandamide

Macrophages

LPS

↑ 2-arachidonyl glycerol
↓ 2-arachidonyl glycerol
hydrolytic activity

Pestonjamasp and Burstein [137]

Dendritic cells

LPS

↑ 2-arachidonyl glycerol

Matias et al. [138]

Monocytes

Induces CB1 receptor
↑ CB2 receptor
RAW 264.7 cells

J774 cells

LPS

LPS

patients [126, 127]. Perhaps, excessive MAPK activation
leads to decreased NF-𝜅B activity as discussed for the LPS
response.The opposing effects on IRF3 and NF-𝜅B activities
indicate that the cannabinoid alters a signaling step downstream of TRIF binding TLR3.
In striking contrast, WIN 55,212-2 has the opposite
effect on interferon-𝛽 mRNA and transcription factor
IRF3 in TLR4-transfected HEK293 cells stimulated with
LPS [126] (Table 1). Likewise, Δ9 -tetrahydrocannabinol and
nonpsychoactive cannabidiol inhibits interferon-𝛽 mRNA
expression and protein secretion in LPS-activated mouse
microglial BV-2 cell line [125]. An antagonist of peroxisome proliferator-activated receptor-𝛼 blocks the enhanced
interferon-𝛽 level without affecting tumor necrosis factor𝛼 level in TLR3-transfected HEK293 cells [127], indicating sensitivity of transcription factor IRF3, but not NF𝜅B, activity to peroxisome proliferator-activated receptor-𝛼.
However, sensitivity of interferon-𝛽 inhibition to the peroxisome proliferator-activated receptor-𝛼 antagonist was not
examined in TLR4-transfected HEK293 cells. The opposing
cannabinoid effects on interferon-𝛽 induced via TLR3 versus
TLR4 signaling pathways (Figure 2) raise the question of
why peroxisome proliferator-activated receptor-𝛼 does not
enhance interferon-𝛽 production in LPS-stimulated cells

↑ anandamide
↑ N-acyltransferase
↑ phospholipase D
↑ anandamide
↑ 2-arachidonyl glycerol
↓ 2-arachidonyl glycerol
hydrolytic activity

Varga et al. [136]

Walter et al. [129]
Mukhopadhyay et al. [132]
Friedman et al. [139]
Liu et al. [23]
Pestonjamasp and Burstein [137]
Di Marzo et al. [140]
Pestonjamasp and Burstein [137]

exposed to cannabinoids, unless the receptor is not activated
during TLR4 signaling. The disparate cannabinoid effect
on interferon-𝛽 production implies two different molecular targets in the TLR3 and TLR4 pathways. Perhaps, the
TRAM:TRIF and TRIF adaptors, or TRAF3 and TRAF6 used
by TLR4 and TLR3, respectively, have differential sensitivity
to cannabinoid immune modulation.
4.2. Impact of Toll-Like Receptor Activation on Endocannabinoid System. Cannabinoid receptor expression by immune
cells varies depending on the cell type, maturational stage,
and activation state. Innate immune cells have a high
degree of plasticity, and their cannabinoid receptor expression can be manipulated intentionally (Table 3). Human
peripheral blood monocytes, human dendritic cells, and
some monocyte/macrophage cell lines constitutively express
both CB1 and CB2 receptors [129, 138, 143]. Maturation of
human peripheral blood monocytes and monocytic THP1 cells and differentiation of human promyelocytic HL60
cell line into macrophages by phorbol esters upregulate
cannabinoid receptor expression [143–145]. Notably, Δ9 tetrahydrocannabinol impairs LPS-mediated differentiation
of human monocytes into dendritic cells [122]. On the other
hand, resident mouse macrophages lack detectable CB1 and
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CB2 receptor mRNA, whereas inflammatory thioglycollateelicited macrophages express a high level of the CB2 receptor, and interferon-𝛾 stimulation may further increase CB2
receptor expression [128]. Microglial cells express no/low
level of CB1 receptor mRNA, and CB2 receptor mRNA is
undetectable [128, 129, 146]. Stimulation of rodent microglial
cells with interferon-𝛾 induces CB2 receptor mRNA expression [129, 130]. The level of cannabinoid receptor expression
on immune cells affects cannabinoid immune modulation.
For example, a nonpsychoactive cannabinoid inhibits LPSinduced interleukin-6 expression only after human monocytes mature into macrophages [147]. Hence, particular
stimuli induce or upregulate cannabinoid receptor expression
during myeloid cell differentiation, maturation, and activation affecting their sensitivity to cannabinoids.
The influence of only TLR4 signal transduction has been
investigated on the endocannabinoid system in myeloid cells
(Table 3). LPS modulation of cannabinoid receptor expression in myeloid cells depends on the experimental system
(Figure 3). For example, CB2 receptor mRNA level drops in
thioglycollate-elicited macrophages in response to LPS [128,
131]. In contrast, LPS activation of mouse macrophage RAW
264.7 cell line induces CB1 receptor mRNA and upregulates
CB2 receptor mRNA expression [129, 132, 139]. Protein
kinases A and C inhibitors partially block the LPS effect on
CB1 and CB2 receptor expression [132], although involvement
of the cAMP-protein kinase A pathway in LPS signaling is
controversial [148]. Likewise, in vivo LPS administration to
rodents upregulates CB2 receptor expression in microglial
cells [132, 133]. Importantly, various pathological conditions
are associated with altered cannabinoid receptor expression,
usually increased CB2 receptor expression [10, 57]. Hence, the
differential LPS impact on cannabinoid receptor expression
may reflect plasticity of innate immune cells to cues from
their microenvironment.
Evidence is growing that endocannabinoid levels change
during various disease processes due to altered catalytic
activities of the biosynthetic or metabolizing enzymes. In several animal disease models, modified endocannabinoid levels
exert pro- or anti-inflammatory effects on innate immune
cells based on enzyme inhibitors, transporter inhibitors, and
mice genetically deficient in the enzymes. This research area
is discussed in detail elsewhere [56, 57, 92, 133, 149].
Danger signals provided to innate immune cells increase
endocannabinoid production (Figure 3). LPS administration
in vivo decreases metabolizing fatty acid amide hydrolase activity in mouse peripheral blood mononuclear cells
[134], which would increase anandamide levels (Table 3).
Similarly, LPS administration also diminishes 2-arachidonyl
glycerol hydrolytic activity within the spleen and liver
[135]. Anandamide is barely detected in rat monocytes
and macrophage J774 cell line, whereas the cells contain
substantial anandamide levels upon LPS stimulation [136,
140]. In addition, LPS activation of rat macrophages and
J774 cells also increases 2-arachidonyl glycerol levels due
to decreased 2-arachidonyl glycerol hydrolytic activity in
the cells [137]. Human immature dendritic cells contain
enhanced 2-arachidonyl glycerol, but not anandamide, levels upon LPS activation [138]. Conversely, low dose-LPS
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PAMP
DAMP
Danger signal

TLR-mediated
cell activation

↑ endocannabinoids
↑ CB receptors

↑ endocannabinoids
↓ CB receptors

Immune
suppression

No immune
suppression

Figure 3: Interaction between TLR-mediated activation and endocannabinoid system. PAMPs and DAMPs provide dangers signals that activate innate immune cells via TLRs. Activated cells
increase endocannabinoid levels that may suppress the inflammatory response. Cell activation may increase or decrease cannabinoid
receptor expression. Increased receptor expression in the presence
of endocannabinoids promotes immune suppression. Decreased
receptor expression may render cells resistant to cannabinoidmediated immune suppression, and the inflammatory response continues. PAMPs: pathogen-associated molecular patterns; DAMPs:
damage-associated molecular patterns; TLR: Toll-like receptors; CB:
cannabinoid.

activation of macrophage RAW 264.7 cell line increases
anandamide, but not 2-arachidonyl glycerol, levels along
with enhanced biosynthetic N-acyltransferase and phospholipase D activities [23, 137]. The rapid time kinetics of
augmented anandamide level [23] indicates a direct effect
of the TLR4 signal transduction pathway as opposed to
autocrine stimulation by secreted cytokines. In support of this
possibility, increased anandamide level in RAW 264.7 cells is
prevented by MAPK and NF-𝜅B inhibitors [23], indicating
involvement of the MyD88-dependent signal transduction
pathway (Figure 2(a)). Although what endocannabinoids
increase during LPS stimulation appears to depend on the cell
type and experimental conditions, higher endocannabinoid
levels are accompanied by increased biosynthetic enzyme
activity and/or decreased metabolizing enzyme activity.

5. Conclusions
When the immune system encounters a pathogen, innate
immune cells recognize the pathogen via TLRs and other
pattern-recognition receptors to trigger an inflammatory
response. Innate immune cells are an important source of
endocannabinoids, and these cells synthesize and metabolize
endocannabinoids. TLR-mediated activation of the innate
immune cells enhances their endocannabinoid levels (Figure 3). In the absence of an infection, tissue damage produces
DAMPs perceived as danger signals via TLRs to activate
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innate immune cells. Indeed, local endocannabinoid production increases in response to tissue damage during disease
progression and infections [150]. Abundant evidence demonstrates that cannabinoids have anti-inflammatory activity,
which is the desired consequence during sterile inflammation. Considering that 2-arachidonyl glycerol behaves as a
chemoattractant [129, 145], locally enhanced endocannabinoid levels may recruit immune cells to the site and mitigate
further tissue damage. Thus, innate immune cells may play
a role in regulating endocannabinoid homeostasis, and, in
turn, the endocannabinoid system modulates local inflammation. TLR signals also alter cannabinoid receptor expression by innate immune cells, which affects their sensitivity
to cannabinoids. During progression of an inflammatory
disease, cells may become refractory to cannabinoid immune
suppression despite elevated endocannabinoid levels, and
the inflammatory response continues and may intensify.
Therefore, the final outcome may be enhanced clearance of
an infection, facilitation of tissue healing, or exacerbation
of tissue damage. Although definition of the link between
cannabinoid and TLR signaling pathways awaits further
studies, identification of promising molecular targets may
provide insights into therapeutic modalities to control injurious inflammation.
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